JAK1 and Alzheimer disease: It is noteworthy that IL-21 signals through the JAK/STAT pathway, and JAK1 inhibitors, such as abrocitinib, baritinib, and updacitinib, have recently been demonstrated to block IL-21R signaling, showing efficacy in AD (124, 125).